TY - JOUR
T1 - Molecular Dynamics Simulations Revealed the Regulation of Ligands to the Interactions between Androgen Receptor and Its Coactivator
AU - Liu, Na
AU - Zhou, Wenfang
AU - Guo, Yue
AU - Wang, Junmei
AU - Fu, Weitao
AU - Sun, Huiyong
AU - Li, Dan
AU - Duan, Mojie
AU - Hou, Tingjun
N1 - Funding Information:
This study was supported by National Major Basic Research Program of China (2016YFA0501701, 2016YFB0201700), National Science Foundation of China (21773298, 21403291, 21575128, 81603031), and National Institutes of Health of USA (R01-GM079383, R21-GM097617).
Funding Information:
This study was supported by National Major Basic Research Program of China (2016YFA0501701, 2016YFB0201700) National Science Foundation of China (21773298, 21403291, 21575128, 81603031), and National Institutes of Health of USA (R01-GM079383, R21-GM097617).
Publisher Copyright:
© 2018 American Chemical Society.
PY - 2018/8/27
Y1 - 2018/8/27
N2 - The androgen receptor (AR) plays important roles in gene expression regulation, sexual phenotype maintenance, and prostate cancer (PCa) development. The communications between the AR ligand-binding domain (LBD) and its coactivator are critical to the activation of AR. It is still unclear how the ligand binding would affect the AR-coactivator interactions. In this work, the effects of the ligand binding on the AR-coactivator communications were explored by molecular dynamics (MD) simulations. The results showed that the ligand binding regulates the residue interactions in the function site AF-2. The ligand-to-coactivator allosteric pathway, which involves the coactivator, helix 3 (H3), helix 4 (H4), the loop between H3 and H4 (L3), and helix 12 (H12), and ligands, was characterized. In addition, the interactions of residues on the function site BF-3, especially on the boundary of AF-2 and BF-3, are also affected by the ligands. The MM/GBSA free energy calculations demonstrated that the binding affinity between the coactivator and apo-AR is roughly weaker than those between the coactivator and antagonistic ARs but stronger than those between the coactivator and agonistic ARs. The results indicated that the long-range electrostatic interactions and the conformational entropies are the main factors affecting the binding free energies. In addition, the F876L mutation on AR-LBD affects the ligand-to-coactivator allosteric pathway, which could be the reason for point mutation induced tolerance for the antagonistic drugs such as enzalutamide. Our study would help to develop novel drug candidates against PCa.
AB - The androgen receptor (AR) plays important roles in gene expression regulation, sexual phenotype maintenance, and prostate cancer (PCa) development. The communications between the AR ligand-binding domain (LBD) and its coactivator are critical to the activation of AR. It is still unclear how the ligand binding would affect the AR-coactivator interactions. In this work, the effects of the ligand binding on the AR-coactivator communications were explored by molecular dynamics (MD) simulations. The results showed that the ligand binding regulates the residue interactions in the function site AF-2. The ligand-to-coactivator allosteric pathway, which involves the coactivator, helix 3 (H3), helix 4 (H4), the loop between H3 and H4 (L3), and helix 12 (H12), and ligands, was characterized. In addition, the interactions of residues on the function site BF-3, especially on the boundary of AF-2 and BF-3, are also affected by the ligands. The MM/GBSA free energy calculations demonstrated that the binding affinity between the coactivator and apo-AR is roughly weaker than those between the coactivator and antagonistic ARs but stronger than those between the coactivator and agonistic ARs. The results indicated that the long-range electrostatic interactions and the conformational entropies are the main factors affecting the binding free energies. In addition, the F876L mutation on AR-LBD affects the ligand-to-coactivator allosteric pathway, which could be the reason for point mutation induced tolerance for the antagonistic drugs such as enzalutamide. Our study would help to develop novel drug candidates against PCa.
UR - http://www.scopus.com/inward/record.url?scp=85049872483&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85049872483&partnerID=8YFLogxK
U2 - 10.1021/acs.jcim.8b00283
DO - 10.1021/acs.jcim.8b00283
M3 - Article
C2 - 29993249
AN - SCOPUS:85049872483
SN - 1549-9596
VL - 58
SP - 1652
EP - 1661
JO - Journal of Chemical Information and Modeling
JF - Journal of Chemical Information and Modeling
IS - 8
ER -